Login to Your Account



$75M Milestone Payment from J&J

Et Tu, Ibrutinib? Pharmacyclics NDA in Lymphomas Accepted

By Randy Osborne
Staff Writer

Thursday, August 29, 2013
Pharmacyclics Inc. gained a $75 million milestone payment from Johnson & Johnson (J&J) unit Janssen Biotech Inc. for progress with the oral Bruton’s tyrosine kinase inhibitor ibrutinib, and the future looks even brighter for the compound, if the FDA grants approval.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription